{"transactions":[{"id":4636211,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":false,"shares":340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":29104,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":340},"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636210,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":17,"price":307.74,"value":5231.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."}],"balance_after":31854,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636209,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":235,"price":307.1911,"value":72189.9085,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31871,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636208,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":404,"price":306.1834,"value":123698.0936,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32106,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636207,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":1535,"price":304.5154,"value":467431.139,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32510,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636206,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":1976,"price":303.5444,"value":599803.7344,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":34045,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636205,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":833,"price":302.5107,"value":251991.4131,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":36021,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636204,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":true,"shares":340,"price":52.27,"value":17771.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."}],"balance_after":36854,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":3608251,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":400,"price":288.9792,"value":115591.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $288.5500 to $289.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":36514,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":3608250,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":385,"price":287.5253,"value":110697.2405,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $287.0500 to $287.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":36914,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":3608249,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":2115,"price":286.3589,"value":605649.0735,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $285.8000 to $286.7700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":37299,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":3608248,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":285.1671,"value":513300.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $284.7500 to $285.7000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":39414,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":3608247,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":300,"price":283.9854,"value":85195.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $283.4300 to $284.1550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41214,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":698020,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":29444,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698019,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":409,"price":292.8191,"value":119763.0119,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.78 to $292.89. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41514,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698018,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":991,"price":291.7119,"value":289086.4929,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $291.57 to $292.47. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41923,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698017,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":200,"price":290.6,"value":58120.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $290.48 to $290.72. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42914,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698016,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":503,"price":289.8022,"value":145770.5066,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $289.33 to $290.18. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43114,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698015,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":356,"price":288.7496,"value":102794.8576,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $288.32 to $289.20. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43617,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698014,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":1214,"price":287.7731,"value":349356.5434,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $287.30 to $288.27. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43973,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698013,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":1032,"price":286.7968,"value":295974.2976,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $286.28 to $287.17. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45187,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698012,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":157,"price":285.7357,"value":44860.5049,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $285.28 to $285.90. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46219,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698011,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":33,"price":284.553,"value":9390.249,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $284.28 to $284.58. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46376,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698010,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":105,"price":284.1375,"value":29834.4375,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $283.24 to $284.23. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46409,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698009,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.27,"value":261350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":46514,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":716399,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":34444,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716398,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":317.1517,"value":190291.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $316.7000 to $317.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41514,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716397,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":315.7775,"value":284199.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $315.4400 to $316.2600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42114,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716396,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":314.5788,"value":31457.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $314.3100 to $314.5900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43014,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716395,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":700,"price":313.4574,"value":219420.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $313.1300 to $314.0100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43114,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716394,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1081,"price":312.2784,"value":337572.9504,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $312.1050 to $312.5300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43814,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716393,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1119,"price":311.72,"value":348814.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $311.0900 to $312.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":44895,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716392,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":104,"price":310.2023,"value":32261.0392,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $310.0100 to $310.2100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46014,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716391,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":396,"price":308.9886,"value":122359.4856,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $308.6300 to $309.6000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46118,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716390,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.27,"value":261350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":46514,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716389,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-06-30","kind":"other","planned":true,"acquired":true,"shares":132,"price":160.7095,"value":21213.654,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":41514,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":755993,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":39444,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755992,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":200,"price":230.41,"value":46082.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":41382,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755991,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1216,"price":229.4676,"value":279032.6016,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $229.0900 to $230.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41582,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755990,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":584,"price":228.5738,"value":133487.0992,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $228.0500 to $228.9650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42798,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755989,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":226.7794,"value":90711.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $226.5250 to $227.0100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43382,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755988,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1432,"price":225.9672,"value":323585.0304,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $225.5200 to $226.3700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43782,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755987,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":677,"price":225.1983,"value":152459.2491,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $224.5100 to $225.4600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45214,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755986,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":491,"price":223.9467,"value":109957.8297,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $223.4250 to $224.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45891,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755985,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.27,"value":261350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":46382,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":794574,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-05T00:20:10.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":44444,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002001011-26-000046","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000046/edgardoc.xml","form_type":"4"}},{"id":794573,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-05-05T00:20:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":800,"price":234.0177,"value":187214.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $233.8200 to $234.1100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41382,"source":{"system":"sec-edgar","filing":"0002001011-26-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000046/edgardoc.xml","form_type":"4"}},{"id":794572,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-05-05T00:20:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":1420,"price":232.922,"value":330749.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $232.5400 to $233.3300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42182,"source":{"system":"sec-edgar","filing":"0002001011-26-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000046/edgardoc.xml","form_type":"4"}},{"id":794571,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-05-05T00:20:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":780,"price":232.0399,"value":180991.122,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $231.5200 to $232.4900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43602,"source":{"system":"sec-edgar","filing":"0002001011-26-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000046/edgardoc.xml","form_type":"4"}},{"id":794570,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-05-05T00:20:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":370,"price":230.8692,"value":85421.604,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $230.4300 to $231.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":44382,"source":{"system":"sec-edgar","filing":"0002001011-26-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000046/edgardoc.xml","form_type":"4"}},{"id":794569,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-05-05T00:20:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":98,"price":229.7086,"value":22511.4428,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $229.4000 to $230.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":44752,"source":{"system":"sec-edgar","filing":"0002001011-26-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000046/edgardoc.xml","form_type":"4"}},{"id":794568,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-05-05T00:20:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":932,"price":228.7537,"value":213198.4484,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $228.4000 to $229.3000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":44850,"source":{"system":"sec-edgar","filing":"0002001011-26-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000046/edgardoc.xml","form_type":"4"}},{"id":794567,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-05-05T00:20:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":227.4493,"value":136469.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $227.0400 to $227.9200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45782,"source":{"system":"sec-edgar","filing":"0002001011-26-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000046/edgardoc.xml","form_type":"4"}},{"id":794566,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-05-05T00:20:10.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.27,"value":261350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":46382,"source":{"system":"sec-edgar","filing":"0002001011-26-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000046/edgardoc.xml","form_type":"4"}},{"id":821499,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-02T22:56:59.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":49444,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002001011-26-000037","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000037/primary_doc.xml","form_type":"4"}},{"id":821498,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-04-02T22:56:59.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":337,"price":204.5026,"value":68917.3762,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.0100 to $204.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41382,"source":{"system":"sec-edgar","filing":"0002001011-26-000037","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000037/primary_doc.xml","form_type":"4"}},{"id":821497,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-04-02T22:56:59.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":963,"price":203.2218,"value":195702.5934,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.9900 to $203.7100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41719,"source":{"system":"sec-edgar","filing":"0002001011-26-000037","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000037/primary_doc.xml","form_type":"4"}},{"id":821496,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-04-02T22:56:59.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":700,"price":201.8971,"value":141327.97,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.6500 to $202.1900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42682,"source":{"system":"sec-edgar","filing":"0002001011-26-000037","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000037/primary_doc.xml","form_type":"4"}},{"id":821495,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-04-02T22:56:59.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1238,"price":200.9429,"value":248767.3102,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.6000 to $201.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43382,"source":{"system":"sec-edgar","filing":"0002001011-26-000037","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000037/primary_doc.xml","form_type":"4"}},{"id":821494,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-04-02T22:56:59.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1302,"price":199.7221,"value":260038.1742,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4600 to $200.3300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":44620,"source":{"system":"sec-edgar","filing":"0002001011-26-000037","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000037/primary_doc.xml","form_type":"4"}},{"id":821493,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-04-02T22:56:59.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":460,"price":198.8493,"value":91470.678,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $198.4000 to $199.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45922,"source":{"system":"sec-edgar","filing":"0002001011-26-000037","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000037/primary_doc.xml","form_type":"4"}},{"id":821492,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-04-02T22:56:59.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.27,"value":261350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":46382,"source":{"system":"sec-edgar","filing":"0002001011-26-000037","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000037/primary_doc.xml","form_type":"4"}},{"id":826813,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-28T00:16:56.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":21525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter."}],"balance_after":21525,"derivative":{"exercise_price":202.55,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":21525},"source":{"system":"sec-edgar","filing":"0002001011-26-000032","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000032/primary_doc.xml","form_type":"4"}},{"id":826812,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-28T00:16:56.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":4513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2027, February 15, 2028 and February 15, 2029, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Pursuant to an election under the Issuer's Nonqualified Deferred Compensation Plan, delivery of shares otherwise issuable upon each vesting date will be deferred."}],"balance_after":41382,"source":{"system":"sec-edgar","filing":"0002001011-26-000032","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000032/primary_doc.xml","form_type":"4"}},{"id":856997,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":54444,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856996,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":1142,"price":208.8724,"value":238532.2808,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $208.6000 to $208.9700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":36869,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856995,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":1446,"price":208.1183,"value":300939.0618,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $207.6700 to $208.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":38011,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856994,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":612,"price":207.0089,"value":126689.4468,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $206.6800 to $207.5100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":39457,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856993,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":340,"price":206.367,"value":70164.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $205.6000 to $206.5400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40069,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856992,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":460,"price":205.178,"value":94381.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.8400 to $205.5700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40409,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856991,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":200,"price":204.17,"value":40834.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $203.8600 to $204.4800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40869,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856990,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":300,"price":201.7,"value":60510.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":41069,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856989,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":93,"price":200.6225,"value":18657.8925,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.5800 to $200.8700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41369,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856988,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":207,"price":199.956,"value":41390.892,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.8800 to $200.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41462,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856987,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":100,"price":199.005,"value":19900.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":41669,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856986,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":100,"price":197.6954,"value":19769.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $197.5800 to $198.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41769,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":856985,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-03-06T23:51:02.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.27,"value":261350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":41869,"source":{"system":"sec-edgar","filing":"0002001011-26-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000024/edgardoc.xml","form_type":"4"}},{"id":898630,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-02-18T21:24:47.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":992,"price":183.83,"value":182359.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":36869,"source":{"system":"sec-edgar","filing":"0002001011-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000013/edgardoc.xml","form_type":"4"}},{"id":898629,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-02-18T21:24:47.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":801,"price":183.83,"value":147247.83,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":37861,"source":{"system":"sec-edgar","filing":"0002001011-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000013/edgardoc.xml","form_type":"4"}},{"id":898628,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-02-18T21:24:47.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":593,"price":183.83,"value":109011.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":38662,"source":{"system":"sec-edgar","filing":"0002001011-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000013/edgardoc.xml","form_type":"4"}},{"id":898627,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-02-18T21:24:47.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":4083,"price":183.83,"value":750577.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs."}],"balance_after":39255,"source":{"system":"sec-edgar","filing":"0002001011-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000013/edgardoc.xml","form_type":"4"}},{"id":898626,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-02-18T21:24:47.000Z","date":"2026-02-14","kind":"grant","planned":false,"acquired":true,"shares":8810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (\"PSUs\")."}],"balance_after":43338,"source":{"system":"sec-edgar","filing":"0002001011-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000013/edgardoc.xml","form_type":"4"}},{"id":898625,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-02-18T21:24:47.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":3211,"price":183.83,"value":590278.13,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs."}],"balance_after":34528,"source":{"system":"sec-edgar","filing":"0002001011-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000013/edgardoc.xml","form_type":"4"}},{"id":898624,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-02-18T21:24:47.000Z","date":"2026-02-14","kind":"grant","planned":false,"acquired":true,"shares":6928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (\"PSUs\")."}],"balance_after":37739,"source":{"system":"sec-edgar","filing":"0002001011-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000013/edgardoc.xml","form_type":"4"}},{"id":1069424,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-08-12T20:34:53.000Z","date":"2025-08-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1325,"price":150.06,"value":198829.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":30811,"source":{"system":"sec-edgar","filing":"0002001011-25-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000061/edgardoc.xml","form_type":"4"}},{"id":1096621,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-07-02T23:32:33.000Z","date":"2025-06-30","kind":"other","planned":false,"acquired":true,"shares":233,"price":91.0775,"value":21221.0575,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":32136,"source":{"system":"sec-edgar","filing":"0002001011-25-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000052/edgardoc.xml","form_type":"4"}},{"id":1103255,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-06-25T00:29:59.000Z","date":"2025-06-23","kind":"sale","planned":false,"acquired":false,"shares":500,"price":114.0843,"value":57042.15,"ownership":{"direct":true},"balance_after":31903,"source":{"system":"sec-edgar","filing":"0002001011-25-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000048/edgardoc.xml","form_type":"4"}},{"id":1114165,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-06-12T21:51:36.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":500,"price":114.5414,"value":57270.7,"ownership":{"direct":true},"balance_after":32403,"source":{"system":"sec-edgar","filing":"0002001011-25-000047","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000047/edgardoc.xml","form_type":"4"}},{"id":1128401,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-06-03T00:06:06.000Z","date":"2025-05-15","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":104,"value":104000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total includes 17 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan."}],"balance_after":32903,"source":{"system":"sec-edgar","filing":"0002001011-25-000037","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000037/edgardoc.xml","form_type":"4"}},{"id":1128400,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-06-03T00:06:06.000Z","date":"2024-08-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":897,"price":100.155,"value":89839.035,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":21637,"source":{"system":"sec-edgar","filing":"0002001011-25-000037","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000037/edgardoc.xml","form_type":"4"}},{"id":1220660,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-06T23:55:43.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":28043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter."}],"balance_after":28043,"derivative":{"exercise_price":115.26,"expiration_date":"2035-03-04","underlying":"Common Stock","underlying_shares":28043},"source":{"system":"sec-edgar","filing":"0002001011-25-000016","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000016/edgardoc.xml","form_type":"4"}},{"id":1220659,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-03-06T23:55:43.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":6415,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":34783,"source":{"system":"sec-edgar","filing":"0002001011-25-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000016/edgardoc.xml","form_type":"4"}},{"id":1261996,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-02-20T01:37:29.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":876,"price":120,"value":105120.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":28368,"source":{"system":"sec-edgar","filing":"0002001011-25-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000010/edgardoc.xml","form_type":"4"}},{"id":1261995,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-02-20T01:37:29.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1114,"price":120,"value":133680.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":29244,"source":{"system":"sec-edgar","filing":"0002001011-25-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000010/edgardoc.xml","form_type":"4"}},{"id":1261994,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-02-20T01:37:29.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1758,"price":120,"value":210960.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units."}],"balance_after":30358,"source":{"system":"sec-edgar","filing":"0002001011-25-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000010/edgardoc.xml","form_type":"4"}},{"id":1261993,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-02-20T01:37:29.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":5429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs)."}],"balance_after":32116,"source":{"system":"sec-edgar","filing":"0002001011-25-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000010/edgardoc.xml","form_type":"4"}},{"id":1261992,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-02-20T01:37:29.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":2775,"price":120,"value":333000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units."}],"balance_after":26687,"source":{"system":"sec-edgar","filing":"0002001011-25-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000010/edgardoc.xml","form_type":"4"}},{"id":1261991,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2025-02-20T01:37:29.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":6928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs)."}],"balance_after":29462,"source":{"system":"sec-edgar","filing":"0002001011-25-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000010/edgardoc.xml","form_type":"4"}},{"id":1399753,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-09-26T00:54:39.000Z","date":"2024-09-23","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":70944,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0002001011-24-000089","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000089/edgardoc.xml","form_type":"4"}},{"id":1399752,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2024-09-26T00:54:39.000Z","date":"2024-09-23","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":99.6005,"value":199201.0,"ownership":{"direct":true},"balance_after":22534,"source":{"system":"sec-edgar","filing":"0002001011-24-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000089/edgardoc.xml","form_type":"4"}}],"next_cursor":"2024-09-26T00:54:39.000000Z,1399752"}